I think overall it was a good IC.
the key things they are dealing with an MDO that could mean big potential sales.
they also addressed the difference in why they are confident pharma will deliver and why APAS is currently not.
big thing is APAS pharma is addressing a market with ongoing automation, clinical not. So we are followers here and not market disruptors.
APAS pharma can analyse 1,000 plates a day. Competitors can do around 112 per day...difference is massive
competitors price circa 600,000 US$
Ann: Quarterly Investor Call, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
